Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies
暂无分享,去创建一个
A. Mastronuzzi | Sofia Reddel | P. Merli | C. Quintarelli | M. Sinibaldi | M. Guercio | B. De Angelis | L. Iaffaldano | R. de Vito | S. Caruso | Z. Abbaszadeh | S. Di Cecca | F. del Bufalo | Roselia Ciccone | M. Lodi | M. Cefalo | Simona Manni | Manuela Ceccarelli | F. Locatelli | Michele Pezzella | Domenico A Silvestris | Alessio Ottaviani | Maria Cecilia Quadraccia | Mariasole Aurigemma | Andrea Sarcinelli
[1] M. Kersten,et al. Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Qihang Sun,et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies , 2021, Journal of Experimental & Clinical Cancer Research.
[3] P. Jacqmin,et al. Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model‐based approach , 2021, British journal of clinical pharmacology.
[4] F. Locatelli,et al. Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies , 2021, Frontiers in Immunology.
[5] J. Zehnder,et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy , 2021, Blood advances.
[6] He Huang,et al. Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma , 2021, Frontiers in Oncology.
[7] Cheng Cheng,et al. Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy , 2021, British journal of haematology.
[8] A. Órfão,et al. Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts , 2021, Journal for ImmunoTherapy of Cancer.
[9] M. Sadelain,et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy , 2021, Nature Reviews Immunology.
[10] Rosalie M Sterner,et al. CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.
[11] Michael R. Green,et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma , 2021, Blood.
[12] F. Locatelli,et al. The role of interferon‐gamma and its signaling pathway in pediatric hematological disorders , 2021, Pediatric blood & cancer.
[13] J. Gauthier,et al. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL , 2020, Bone Marrow Transplantation.
[14] A. Rapoport,et al. Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes. , 2020, Neuro-oncology.
[15] L. Meng,et al. Macrophage, the potential key mediator in CAR-T related CRS , 2020, Experimental Hematology & Oncology.
[16] H. Kotani,et al. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy , 2019, British journal of haematology.
[17] D. Porter,et al. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] S. Grupp,et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[19] C. Doglioni,et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.
[20] Toshio Tanaka,et al. Immunotherapeutic implications of IL-6 blockade for cytokine storm. , 2016, Immunotherapy.
[21] C. Hunter,et al. IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.
[22] S. Grupp,et al. Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.
[23] G. Schulert,et al. Macrophage activation syndrome and cytokine-directed therapies. , 2014, Best practice & research. Clinical rheumatology.
[24] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[25] J. Szmydynger-Chodobska,et al. Blood–Brain Barrier Pathophysiology in Traumatic Brain Injury , 2011, Translational Stroke Research.
[26] N. Nishimoto,et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.
[27] A. Billiau,et al. Modification of the anti‐CD3‐induced cytokine release syndrome by anti‐interferon‐γ or anti‐interleukin‐6 antibody treatment: Protective effects and biphasic changes in blood cytokine levels , 1993, European journal of immunology.